EVR

$278.69

Post-MarketAs of Mar 17, 8:00 PM UTC

Evercore Inc., together with its subsidiaries, operates as an independent investment banking firm in the Americas, Europe, Middle East, Africa, and Asia-Pacific.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JPMBACGS

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$278.69
Potential Upside
21.1%
Whystock Fair Value$337.39
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorFinancial Services
IndustryCapital Markets

Evercore Inc., together with its subsidiaries, operates as an independent investment banking firm in the Americas, Europe, Middle East, Africa, and Asia-Pacific. The company operates through two segments, Investment Banking & Equities, and Investment...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$11.04B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.84
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.57
Div Yield
Strong income play. Yield provides a meaningful total return floor.
123.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
30.07%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.28

Recent News

Zacks
Mar 17, 2026

3 Investment Bank Stocks to Buy From a Flourishing Industry

Efforts to boost operating efficiency, solid trading performance and momentum in underwriting and advisory businesses will aid Zacks Investment Bank industry players, like Morgan Stanley (MS), Interactive Brokers and Evercore (EVR).

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 15, 2026

Evercore Hire Signals Deeper Biotech Equity Focus For Investors

Evercore (NYSE:EVR) has hired David Ke as a Senior Managing Director in its equity capital markets group. Ke is an experienced biotechnology investment banker, joining to expand the firm’s biotechnology equity capital markets capabilities. The move is intended to deepen Evercore’s expertise and client service for biotech companies seeking equity financing. For you as an investor watching NYSE:EVR, this hire points to a clearer focus on biotechnology within Evercore’s equity capital markets...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Barrons.com
Mar 13, 2026

Lennar Earnings Miss Is a Bad Sign for Home Builder Stocks-Even if They’re Rising Today

The company’s 16,863 deliveries, a measure of home closings, missed both guidance and consensus expectations, which called for 17,698.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
StockStory
Mar 13, 2026

Affiliated Managers Group, PJT, Moelis, Jefferies, and Evercore Shares Are Falling, What You Need To Know

A number of stocks fell in the afternoon session after investors raised concerns over the stability of the private credit market, following a key announcement from a major bank. JPMorgan Chase announced it would be restricting lending to private credit providers. This decision came after the bank marked down the value of several loans in its portfolio, signaling potential stress in this rapidly growing corner of the finance world. The move sparked broader industry jitters, leading to a rush for

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 10, 2026

Why Evercore’s Higher Price Target Still Leaves Clearway (CWEN) Rated In-Line

Clearway Energy, Inc. (NYSE:CWEN) is one of the 10 Best Renewable Energy Stocks to Buy Now. As of March 7, 2026, Wall Street’s consensus 12-month price target on the stock stood at $40.14, implying about 6.25% upside from its $37.78 trading price. Analyst targets ranged from $34 to $45, while the stock carried a Moderate […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.